Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies

Breast cancer stem cell antigens as targets for immunotherapy

(2020) Elena Quaglino et al.   SEMINARS IN IMMUNOLOGY

Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer

(2020) Xiaoguang Liu et al.   NATURE CELL BIOLOGY

Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer

(2020) Laura Conti et al.   Cancer Immunology Research

Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer

(2020) Valeria Rolih et al.   Cancers

Cancer stem cell antigens as targets for new combined anti-cancer therapies

(2020) Elena Quaglino et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

(2019) Hideaki Ogiwara et al.   CANCER CELL

Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53

(2019) Yufei Wang et al.   EMBO REPORTS

Novel mouse model for evaluating in vivo efficacy of xCT inhibitor

(2019) Ryosuke Yoshioka et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma

(2019) Kewen Hu et al.   JOURNAL OF CLINICAL INVESTIGATION

Fighting breast cancer stem cells through the immune-targeting of the xCT cystine–glutamate antiporter

(2018) Roberto Ruiu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: potential targets by sulfasalazine

(2018) Fumitaka Wada et al.   CANCER SCIENCE

Drug discovery targeting the mTOR pathway

(2018) Alberto M. Martelli et al.   CLINICAL SCIENCE

The prognostic value of PI3K mutational status in breast cancer: A meta-analysis

(2018) Navid Sobhani et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression

(2018) Xiangming Ji et al.   ONCOGENE

Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells

(2018) Kamil Lisek et al.   Oncotarget

The p53 Tumor Suppressor in the Control of Metabolism and Ferroptosis

(2018) Keerthana Gnanapradeepan et al.   Frontiers in Endocrinology

p53-Autophagy-Metastasis Link

(2018) Tatiana Denisenko et al.   Cancers

AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc– Activity

(2018) Xinxin Song et al.   CURRENT BIOLOGY

Cancer stem cells: A brief review of current status

(2018) Alican Kuşoğlu et al.   GENE

p53 Functions in Adipose Tissue Metabolism and Homeostasis

(2018) Jelena Krstic et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells

(2018) Naoise C. Synnott et al.   Translational Oncology

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246

(2018) Lena Haffo et al.   Scientific Reports

Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells

(2018) Gaetano Donofrio et al.   OncoImmunology

CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549 cells

(2018) Sayo Horibe et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants

(2018) Sara Ibrahim Omar et al.   Oncotarget

The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate

(2017) Pranavi Koppula et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation

(2017) Takeo Goji et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT

(2017) Yuchao Gu et al.   MOLECULAR CELL

ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner

(2017) D Chen et al.   ONCOGENE

Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT

(2017) Evan C. Lien et al.   Science Signaling

SLC7A11 Overexpression in Glioblastoma Is Associated with Increased Cancer Stem Cell-Like Properties

(2017) Monika D. Polewski et al.   STEM CELLS AND DEVELOPMENT

The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility

(2017) Chun-Shik Shin et al.   Nature Communications

Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation

(2017) David S. Liu et al.   Nature Communications

Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells

(2017) Emmanuel Dornier et al.   Nature Communications

Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT

(2017) Evan C. Lien et al.   Science Signaling

Identification of capsazepine as a novel inhibitor of system xc− and cancer-induced bone pain

(2017) Jennifer Fazzari et al.   Journal of Pain Research

A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo

(2017) Elisabetta Bolli et al.   OncoImmunology

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

(2017) Anne Perdrix et al.   Cancers

The PI3K/AKT Pathway as a Target for Cancer Treatment

(2016) Ingrid A. Mayer et al.   Annual Review of Medicine

Increased Expression of System x c − in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance

(2016) Monika D. Polewski et al.   MOLECULAR CANCER RESEARCH

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer

(2016) Dawid Walerych et al.   NATURE CELL BIOLOGY

PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells

(2016) NOBUHISA YOSHIKAWA et al.   ONCOLOGY REPORTS

mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle

(2016) I. Ben-Sahra et al.   SCIENCE

Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity

(2016) Anusha Sriraman et al.   Oncotarget

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation

(2016) Phaik Ju Teoh et al.   Oncotarget

Targeting cancer stem cells with p53 modulators

(2016) Zhan Zhang et al.   Oncotarget

Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis

(2016) Tina Sehm et al.   Oncotarget

Cancer drug resistance: redox resetting renders a way

(2016) Yuan Liu et al.   Oncotarget

The role of p53 in cancer drug resistance and targeted chemotherapy

(2016) Karin Hientz et al.   Oncotarget

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy

(2016) Vladimir J. N. Bykov et al.   Frontiers in Oncology

Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility

(2015) Marie-Helene Larraufie et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer

(2015) S. Lanzardo et al.   CANCER RESEARCH

Tankyrase Inhibition Blocks Wnt/ -Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

(2015) O. Arques et al.   CLINICAL CANCER RESEARCH

Ferroptosis as a p53-mediated activity during tumour suppression

(2015) Le Jiang et al.   NATURE

Expression of xCT and activity of system x c − are regulated by NRF2 in human breast cancer cells in response to oxidative stress

(2015) Eric Habib et al.   Redox Biology

Targeting antioxidants for cancer therapy

(2014) Andrea Glasauer et al.   BIOCHEMICAL PHARMACOLOGY

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

The paradigm of mutant p53-expressing cancer stem cells and drug resistance

(2014) Yoav Shetzer et al.   CARCINOGENESIS

Regulation of Ferroptotic Cancer Cell Death by GPX4

(2014) Wan Seok Yang et al.   CELL

How theTP53Family ProteinsTP63andTP73Contribute to Tumorigenesis: Regulators and Effectors

(2014) Eleonora Candi et al.   HUMAN MUTATION

Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition

(2014) P. Ye et al.   MOLECULAR AND CELLULAR BIOLOGY

Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis

(2014) Scott J Dixon et al.   eLife

p53 Family and Cellular Stress Responses in Cancer

(2014) Johanna Pflaum et al.   Frontiers in Oncology

Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target

(2013) Luika A. Timmerman et al.   CANCER CELL

The noninflammatory role of high mobility group box 1/toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells

(2013) Laura Conti et al.   FASEB JOURNAL

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

(2013) X Peng et al.   Cell Death & Disease

The Cystine/Glutamate Antiporter System xc− in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities

(2012) Jan Lewerenz et al.   ANTIOXIDANTS & REDOX SIGNALING

Glutathione synthesis

(2012) Shelly C. Lu   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

(2012) Scott J. Dixon et al.   CELL

p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis

(2012) Angelina V. Vaseva et al.   CELL

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

The p53 network: cellular and systemic DNA damage responses in aging and cancer

(2012) H. Christian Reinhardt et al.   TRENDS IN GENETICS

Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation

(2011) Teng Ma et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells

(2010) Debora Russo et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Differences in the transactivation domains of p53 family members: a computational study

(2010) Jagadeesh N Mavinahalli et al.   BMC GENOMICS

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab

(2010) Allan Lipton et al.   CANCER

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA

(2010) Carolyn Y. Zhao et al.   CELL CYCLE

p53 and autophagy in cancer: Guardian of the genome meets guardian of the proteome

(2010) Kevin M. Ryan   EUROPEAN JOURNAL OF CANCER

MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells

(2009) Wenrui Duan et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

Transcriptional control of human p53-regulated genes

(2008) Todd Riley et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity

(2008) M. Sauer et al.   NUCLEIC ACIDS RESEARCH

Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/β-catenin pathway

(2008) R-S Chen et al.   ONCOGENE